tiprankstipranks
Trending News
More News >
LAVA Therapeutics (LVTX)
NASDAQ:LVTX
US Market
Advertisement

LAVA Therapeutics (LVTX) Drug Pipeline

Compare
164 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Lava-1207, Lava-1207 Plus Pembrolizumab
Metastatic Castration Resistant Prostate Cancer
Phase I
Terminated
Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer
Apr 29, 2022
Lava-051, Interleukin 2
Multiple Myeloma, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
Phase I
Terminated
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
May 03, 2021

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does LAVA Therapeutics (LVTX) have in its pipeline
      LVTX is currently developing the following drugs: Lava-1207, Lava-1207 Plus Pembrolizumab, Lava-051, Interleukin 2. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis